Meeting
2012 ASCO Annual Meeting
An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma.
Authors
James M. G. Larkin
Royal Marsden Hospital, London, United Kingdom
James M. G. Larkin , Paola Queirolo , Ana M Arance , Axel Hauschild , Michele Del Vecchio , Grant A. McArthur , Bart Neyns , Jürgen C. Becker , Johan Hansson , David Hogg , Paolo Antonio Ascierto , Carmen Loquai , Enrique Espinosa , Claus Garbe , Poulam M Patel , Jacob Schachter , Lada Mitchell , Maria Luisa Veronese , Christian U. Blank , Michael Paul Brown
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma
Clinical Trial Registration Number
NCT01307397
Citation
J Clin Oncol 30, 2012 (suppl; abstr 8517)
DOI
10.1200/jco.2012.30.15_suppl.8517
Abstract #
8517
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma.
First Author: James M. G. Larkin
Poster
2017 ASCO Annual Meeting
Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.
First Author: Ryan J. Sullivan
Poster
2015 ASCO Annual Meeting
A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).
First Author: Asim Amin
Poster
2024 ASCO Annual Meeting
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
First Author: Ahmad A. Tarhini